HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.
ICC 2019

Weimin Cai

Weimin Cai, Speaker at Oncology Conference
School of Pharmacy of Fudan University, China
Title : Association of SPARC and CYP3A5 polymorphisms with peripheral neuropathy induced by nab-paclitaxel in chinese cancer patients


Objective: Genetic polymorphisms of drug metabolic enzymes, transporters and target receptors may account for the interindividual variability of unpredictable peripheral neuropathy induced by nab-paclitaxel. This study aims to identify the biomarkers for peripheral neuropathy induced by nab-paclitaxel in Chinese cancer patients.
Methods: A total of 92 Chinese Han cancer patients were included in the study. Twelve single nucleotide polymorphisms (SNPs) in SPARC, CYP1B1, CYP2C8, CYP3A5, MAPT and TUBB2A were genotyped using the SNAPshot technique. Peripheral neuropathy induced by nab-paclitaxel during the treatment was evaluated according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version 4.03. The effects of genetic variants on peripheral neuropathy induced by nab-paclitaxel were assessed.
Results: Patients who carried the SPARC rs1059829 or rs1053411 mutant alleles had higher risks for grade ≥2 peripheral neuropathy induced by nab-paclitaxel (rs1059829 A allele: odds ratio [OR] = 2.072, 95% confidence interval [CI] = 1.120–3.833, P = 0.0194; rs1053411 C allele: OR = 1.939, 95% CI = 1.042–3.607, P = 0.0353). We also found a significant association between the CYP3A5 rs776746 mutant allele and a lower risk for grade ≥2 peripheral neuropathy (OR = 0.5013, 95% CI = 0.2623–0.9581, P = 0.0352). However, when we considered the Bonferroni correction, the associations between these three SNPs and grade ≥2 peripheral neuropathy were not significant. No association between other genotypes and grade ≥2 peripheral neuropathy was found in this study (P > 0.05).
Conclusions: Several polymorphisms from genes encoding metabolic enzymes and transporters of nab-paclitaxel may be involved in peripheral neuropathy in Chinese cancer patients.


Dr. Weimin Cai received his doctoral degree in pharmacology in 2000 from Nanjing Medical University。During 1992~1994, Dr. Cai went to United States to study clinical pharmacy under the scholarship of WHO. Postdoctoral training in pharmacogenomics was completed at the University of Kentucky, College of Pharmacy, USA in 2001. Dr. Cai is currently chair and professor of Department of Clinical Pharmacy, School of Pharmacy of Fuan University. His research interests include clinical pharmacy and pharmacogenetics. He published more than 170 research papers in well-known journals, including more than 70 articles cited by SCI. He has held many elective offices in professional societies and is also the vice editor-in-chief of China Pharmacist.